Engineered exosomes shut down pancreatic tumor growth in mice
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to an MD Anderson study led by Valerie LeBleu, Ph.D., assistant professor of Cancer Biology, and Sushrut Kamerkar, Ph.D., recent graduate of the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.
Earlier MD Anderson investigations...
Biomarkers predict response to breast cancer treatment
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been the inability to predict who will respond to standard...
Two combination therapies shrink melanoma brain metastases in more than half of patients
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
Targeting a genetic mutation that causes many cancers
A study at MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene that is found in many cancers. The pre-clinical study combined therapies targeting the inhibitors polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK). The findings were published recently in Science Translational Medicine.
Mutations in the RAS gene...
A diverse gut bacteria may slow metastatic melanoma
Researchers at MD Anderson Cancer Center have found that the blend of bacteria in the digestive tract of metastatic melanoma patients is associated...